Results 11 to 20 of about 2,109,479 (260)

Identification and characterization of factor XI autoantibodies in 2 patients with systemic lupus erythematosus: insights into mechanisms of acquired factor XI deficiency [PDF]

Research and Practice in Thrombosis and Haemostasis
Background: Factor (F)XI is a zymogen that contributes to thrombin generation through activation of FIX. Patients with a complete absence of FXI are prone to developing alloantibody inhibitors after replacement therapy.
Priyanka Srivastava, Amy Zhou, Christine Fuja, Charles S. Eby, Gail Baxter, Anton Matafonov, Serena Fedorov, Miriam Brown, Michael Pettit, Benjamin F. Tillman, David Gailani, Jeremy W. Jacobs   +11 more
doaj   +2 more sources

Biology of factor XI.

Blood
AbstractUnique among coagulation factors, the coagulation factor XI (FXI) arose through a duplication of the gene KLKB1, which encodes plasma prekallikrein. This evolutionary origin sets FXI apart structurally because it is a homodimer with 2 identical subunits composed of 4 apple and 1 catalytic domain.
Moellmer SA, Puy C, McCarty OJT.
europepmc   +3 more sources

Factor XI Inhibitors: A New Horizon in Anticoagulation Therapy [PDF]

Cardiology and Therapy
Anticoagulation therapy has undergone significant evolution, marked by the emergence of direct oral anticoagulants with distinct advantages. Despite these advancements, challenges persist in managing residual thrombotic and bleeding risks, particularly ...
João Presume, Jorge Ferreira, Regina Ribeiras   +2 more
doaj   +2 more sources

A Systematic Review of Factor XI/XIa Inhibitors Versus Direct Oral Anticoagulants in Patients with Atrial Fibrillation [PDF]

Clinical and Applied Thrombosis/Hemostasis
Background Atrial fibrillation (AF) is a leading cause of stroke, necessitating effective anticoagulation. While direct oral anticoagulants (DOACs) have improved stroke prevention, bleeding risks remain a concern.
Zhengbiao Xue MS, Song Liao MS, Haiye Fan MS, Yu Shen MS, Zhi Nie MS   +4 more
doaj   +2 more sources

Factor XI and Heart Failure. [PDF]

Arterioscler Thromb Vasc Biol
Gailani D.
europepmc   +3 more sources

Factor XI/XIa Inhibition: The Arsenal in Development for a New Therapeutic Target in Cardio- and Cerebrovascular Disease

Journal of Cardiovascular Development and Disease, 2022
Despite major advancements in the development of safer and more effective anticoagulant agents, bleeding complications remain a significant concern in the treatment of thromboembolic diseases. Improvements in our understanding of the coagulation pathways
Juan J. Badimon, Gines Escolar, M. Urooj Zafar   +2 more
doaj   +1 more source

Reducing Plasma Factor XI Concentration With siRNA Technology [PDF]

JACC: Basic to Translational Science
David Gailani, MD
doaj   +2 more sources

Antithrombotic Effects of the Novel Small-Molecule Factor XIa Inhibitor Milvexian in a Rabbit Arteriovenous Shunt Model of Venous Thrombosis

TH Open, 2023
Background Factor XIa (FXIa) is an emerging therapeutic target, and FXIa inhibition is a promising mechanism to improve therapeutic index over current anticoagulants. Milvexian (BMS-986177/JNJ-70033093) is an oral small-molecule FXIa inhibitor.
Xinkang Wang, Qiu Li, Fuyong Du, Neetu Shukla, Andrea R. Nawrocki, Madhu Chintala   +5 more
doaj   +1 more source

Factor XI Deficiency

Hematology/Oncology Clinics of North America, 2021
Factor XI (FXI) deficiency (hemophilia C or Rosenthal disease) was first described in the 1950s in a multigenerational family experiencing bleeding related to surgery and dental procedures. Managing patients with FXI deficiency presents several challenges, including a lack of correlation of bleeding symptoms with FXI activity levels, the large volume ...
Magdalena Dorota, Lewandowska, Jean Marie, Connors   +1 more
openaire   +2 more sources

Factor XI activity and factor XI antigen in homozygous and heterozygous factor XI deficiency [PDF]

Blood, 1976
A relatively potent antiserum against highly purified, unactivated human factor XI antigen was raised in a rabbit. This antiserum, after concentration, neutralized 50% of the factor XI clotting activity of a standard normal plasma at an antiserum dilution of 1/900.
A, Rimon, S, Schiffman, D I, Feinstein, S I, Rapaport   +3 more
openaire   +3 more sources